miR-15b-3p promotes the malignant progression of endometrial cancer cells through targeting KLF2.

Human endometrial cancer is one of the most common malignant tumors in women with an increased incidence by years. The biological function of miR-15b-3p in endometrial cancer is still unclear. Therefore, this study explores the expression and potential mechanism of miR-15b-3p in endometrial cancer, providing a novel theory basis for targeted therapy. Herein, differentially expressed miRNAs and mRNAs in endometrial cancer were determined by bioinformatics analysis. qRT-PCR measured expression of miRNAs and mRNAs. The protein expression of mRNA in cells was determined by western blot. MTT, wound healing, and Transwell assays evaluated the biological behavior of cells. Dual luciferase assay validated the targeted relationship between target miRNA and mRNA. miR-15b-3p was highly expressed in endometrial cancer, and overexpression of miR-15b-3p promoted the malignant progression of endometrial cancer cells. KLF2 was a downstream target of miR-15b-3p, and overexpression of KLF2 reversed the facilitation of miR-15b-3p on endometrial cancer cells. miR-15b-3p promoted the proliferation, migration, and invasion of endometrial cancer cells by targeting KLF2, which made miR-15b-3p a potential diagnostic factor and new molecular therapeutic target for endometrial cancer.

The synergistic effect of 2,3,5,4'-Tetrahydroxystilbene-2-O-ß-d-glucoside combined with Adriamycin on MCF-7 breast cancer cells.

OBJECTIVE: Breast cancer has been reported to be a serious disease and a threat to women's health. 2,3,5,4'-Tetrahydroxystilbene-2-O-ß-d-glucoside (THSG) is a bioactive natural compound originating from Polygonum multiflorum Thunb., which has been shown to possess anti-inflammatory and antitumor properties. Adriamycin (ADM) is a chemotherapy agent used in tumor therapy that is limited by its side effects. However, little is known about the synergistic effect of THSG combined with ADM on breast cancer. This study seeks to investigate the effects of the combination of THSG plus ADM on MCF-7 breast cancer cells and to test the mechanisms involved. MATERIALS AND METHODS: MTT assay was detected to determine cell viability. Furthermore, cell apoptosis was tested by flow cytometry and TUNEL assay. In addition, protein expression was measured by Western blot analysis. RESULTS: The individual treatment of THSG and ADM induced cell injury. Moreover, cotreatment further increased it, which the effect may be associated with the elevation of the apoptotic-related protein expression such as Bax/Bcl-2 and cleaved caspase-3/caspase-3. Lastly, our results also show the reduction of vascular endothelial growth factor/phosphatidylinositol 3-kinase/Akt protein expression in the individual or synergistic treatment. CONCLUSION: Taken together, cotreatment of THSG and ADM may exert a synergistic reduction of cell injury via the inhibition of vascular endothelial growth factor/phosphatidylinositol 3-kinase/Akt pathway. Thus, THSG might possess potent anti-breast cancer effect with ADM.

Radiologic findings of primary pulmonary angiosarcoma: A case report.

RATIONALE: Primary pulmonary angiosarcoma is a rare disease. Here, we report the case of primary pulmonary angiosarcoma diagnosed computed tomographic pulmonary angiography (CTPA) and discuss its specific imaging characteristics. PATIENT CONCERNS: A 46-year-old man was admitted for cough and shortness of breath. Thoracic CTPA images demonstrated a high-attenuation lesion surrounding by a halo sign in upper lobe of right lung, and the dilated vessel was also seen in lower lobe of right lung. The sign of "hillside sign" was observed on CTPA. DIAGNOSES: It was diagnosed with primary pulmonary angiosarcoma. INTERVENTIONS: Right thoracotomy and right upper lobe lobectomy were performed. OUTCOMES: Five years later, the patient dead of complete occlusion of the pulmonary artery owing to tumor recurrence. LESSONS: Although primary pulmonary angiosarcoma is a rare disease with atypical early clinical symptoms, and it is often misdiagnosed as pulmonary embolism and pulmonary infection. Therefore, it is important to recognize the CTPA imaging characteristics of primary pulmonary angiosarcoma and Surgical resection should be performed to prolong the patients' lifetime.

[Clinicopathologic characteristics of breast cancer with basal-like immunophenotype].

OBJECTIVE: To study the clinicopathologic characteristics of basal-like immunophenotype breast cancer (BLBC). METHODS: 458 cases of female infiltrative breast cancer were studied using immunohistochemical staining with an antibody panel of ER, PR, HER2, Ki-67, CK5/6, CK14 and epidermal growth factor receptor (EGFR) and were classified basing on the immunophenotypes. The clinicopathologic characteristics were compared with other immunophenotypes of breast cancer. 228 of 458 cases of breast cancer were followed up. RESULTS: 46 cases of BLBC were screened out among the 458 breast cancers. And histological features of BLBC were analysed including the larger diameter of cancer foci (average 3.3 cm), appearance of squeezing phenomenon of neighboring cell borders (58.7%, 27/46), geography-like distribution of necrosis (52.2%, 24/46), central zone fibrosis (30.4%, 14/46) and lymphoplasmacytic infiltration at the margin and stroma (63.0%, 29/46). There were nuclear pleomorphism with numerous mitoses. The cancer cells were closely arranged, forming irregular solid architectures. There was a high expression (> 25%) of Ki-67 (43.5%, 20/46). CK5/6, CK14 and EGFR were positive in 58.7% (27/46), 43.5% (20/46) and 65.2% (30/46) respectively. 3-year survival rate of BLBC was 66.9%, lower than the luminal A breast cancer and similar to HER2 over-expression breast cancer. CONCLUSIONS: The proportion of BLBC in the group of breast cancers is 10%. BLBC has its distinct histological and cytological features. Currently, it is still necessary to depend on immunophenotyping in making a BLBC diagnosis. BLBC is the one of breast cancer subtypes with the poorest prognosis.

[Validation method for bacteria and fungi count in microbial limit test of drugs].

OBJECTIVE: To establish the validation method and criteria for counting bacteria and fungi in microbial limit test which is described in the Pharmacopeia of China (ChP) 2005. METHOD: According to the method set up for validation, the tested microorganisms with known counts were added to samples followed by the determination of the recovery. RESULT: With different preparing method for testing samples, the recoveries for the tested microorganisms in testing samples were found to be over 70%. CONCLUSION: Validation method for counting contaminated bacteria and fungi in drugs is recommended to follow the method established in this paper. The recovery for tested microorganisms should be not less than 70%.